Medtronic Hints At Greater Diagnostic Focus
At the IATI Biomed conference held in Tel Aviv in May, Medtronic executives hint at an increasing focus on diagnostics, personalized medicine, and patient outcomes.
You may also be interested in...
Medtronic hopes the $200 million purchase of telehealth firm Cardiocom will enhance its ability to respond to increasing demands on hospitals to better manage patient outcomes and costs. It will also greatly expand its customer base.
The model, more common with high-cost gene therapies, is designed to de-risk use of the drug for hospitals in the event that patients with COVID-19-related ARDS do not survive.
Soon-to-start digital transformation initiatives at the major Japanese pharma firm will focus on in-housing of IT systems and company-wide enhancement of AI/data analytics skills.